Changing focus in diabetes: From glucose to CV risk management
Prof. Jacob gives an overview of new antidiabetic interventions that showed a reduction in CV and total mortality in CV risk patients, which seems to be independent of improved glycemic control.
Video navigation menu
- HbA1c and its associations 00:51
- Is reducing HbA1c really successful? 02:16
- Is there new hope with new agents? 04:49
- Multifactorial effects of new antidiabetic treatments 06:37
- Evolution of T2DM management 07:21
This lecture was part of a CME accredited symposium: "Targeting SGLT2 in clinical cardiology: Exploring the benefits in CV Risk, Diabetes & Heart failure" during ESC 2018 in Munich, Germany.
Prof Stephan Jacob, MD - endocrinologist/diabetologist, University of Tübingen and Cardio Metabolic Institute, Villingen-Schwenningen, Germany
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim/Lilly.